Bill Haney, Dragonfly Therapeutics CEO (Photo by Dave Pedley/Getty Images for SXSW)
May 2, 2022 08:30 AM EDT
Deals
Bioregnum

Gilead joins a line­up of Big Phar­ma part­ners bet­ting big on TriN­KETs, with a $300M cash ante to get start­ed on a 5T4

John Carroll

Editor & Founder

Bill Haney’s Drag­on­fly Ther­a­peu­tics is mak­ing the vault be­tween biotech start­up and the next big lev­el: adding clin­i­cal-stage com­pounds to its own fledg­ling pipeline while …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times